Roche Uses Recursion AI to Uncover New Brain Disease Targets

Roche has partnered with the biotechnology firm Recursion to utilize artificial intelligence in the identification of new biological targets for treating brain diseases. By applying machine learning to large-scale biological datasets, the collaboration aims to improve the efficiency of drug discovery and reduce the high failure rate typically associated with clinical trials.